“GLP-1s cause pancreatic cancer.”
What the evidence shows
This is a distinct question from pancreatitis (inflammation) and from the rodent-based thyroid C-cell warning. A 2025 systematic review and meta-analysis of randomized trials (Wen et al.) found no significant association between GLP-1 use and pancreatic cancer overall (relative risk about 1.30, 95% CI 0.86–1.97, not statistically significant). Larger pooled analyses and cohort studies have been broadly reassuring, with some even suggesting lower cancer risk in people with obesity — plausible, since obesity and diabetes are themselves risk factors that the drugs help address.
What we still don’t know
Pancreatic cancer often takes many years to develop, and most trial follow-up spans only a few years, so a small long-term effect can't be completely excluded. One subgroup slice of the 2025 meta-analysis showed a blip when sorted by background diabetes medication, but the authors themselves said it should be read "with extreme caution" given the few studies involved. In short: no signal in the strongest evidence, but the file isn't permanently closed on a slow-growing cancer.
Why the claim misleads
Flatly stating "GLP-1s cause pancreatic cancer" asserts proven human causation that the data specifically do not show. It likely borrows fear from the separate, unsettled pancreatitis discussion and the rodent thyroid warning and welds them onto a different disease. The evidence-based read is close to the opposite of the myth: current studies find no increased pancreatic-cancer risk, with continued monitoring appropriate for a long-latency cancer.
Graded by The Peptide Era · evidence, not hype